Literature DB >> 20016051

Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers.

Maria Gabriela Valle Gottlieb1, Ivana Beatrice Mânica da Cruz, Marta M F Duarte, Rafael Noal Moresco, Mário Wiehe, Carla Helena Augustin Schwanke, Luiz Carlos Bodanese.   

Abstract

CONTEXT: Metabolic syndrome (MS) is described as a cluster of cardiometabolic risk factors. Studies suggest that ischemia-modified albumin (IMA) is a biomarker of cardiovascular diseases. IMA levels could be associated with cardiometabolic risks and represent a possible indication of microvascular dysfunction in MS patients.
OBJECTIVE: To confirm this possible association, we evaluated the association between IMA levels and MS.
DESIGN: We performed a case-control study (32 healthy individuals and 74 subjects with MS) to evaluate the association between MS, IMA, and other biomarkers [high-sensitivity C-reactive protein (hs-CRP), oxidized low-density lipoprotein (OxLDL), oxidized low-density lipoprotein autoantibodies (anti-OxLDL), IL-6, lipid profile, and glucose].
RESULTS: The MS group showed higher levels of IMA (0.618 +/- 0.1355) as well as higher levels of hs-CRP, OxLDL, anti-OxLDL, and IL-6 than did control subjects (IMA = 0.338 +/- 0.0486) (P < 0.01). Multivariate analysis showed that IMA and MS association was independent of sex, age, diabetes mellitus 2, and hypercholesterolemia.
CONCLUSION: We found an association between IMA and MS. Additional studies including prospective genetic variation approaches need to be performed to help elucidate this association between IMA and MS and its potential clinical role.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016051      PMCID: PMC2840868          DOI: 10.1210/jc.2009-1592

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  The search for a biomarker of cardiac ischemia.

Authors:  David A Morrow; James A de Lemos; Marc S Sabatine; Elliott M Antman
Journal:  Clin Chem       Date:  2003-04       Impact factor: 8.327

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report.

Authors:  D Bar-Or; E Lau; J V Winkler
Journal:  J Emerg Med       Date:  2000-11       Impact factor: 1.484

4.  Does ischemia-modified albumin add prognostic value to the Thrombolysis In Myocardial Infarction risk score in patients with ST-segment elevation myocardial infarction treated with primary angioplasty?

Authors:  Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Alejandro Jimenez-Sosa; Sima Samimi-Fard; Hernandez-Baldomero Idaira
Journal:  Biomarkers       Date:  2009-02       Impact factor: 2.658

5.  Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T.

Authors:  Debashis Roy; Juan Quiles; Guillermo Aldama; Manas Sinha; Pablo Avanzas; Ramón Arroyo-Espliguero; David Gaze; Paul Collinson; Juan Carlos Kaski
Journal:  Int J Cardiol       Date:  2004-11       Impact factor: 4.164

6.  Ischemia-modified albumin predicts mortality in ESRD.

Authors:  Rajan Sharma; David C Gaze; Denis Pellerin; Rajnikant L Mehta; Helen Gregson; Christopher P Streather; Paul O Collinson; Stephen J D Brecker
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

7.  Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases.

Authors:  Aline K Mastella; Rafael N Moresco; Dievan Bisognin da Silva; Aline M Becker; Marta M M F Duarte; Letícia L Giovelli; Sandra Huber da Silva; Luana Rossato; Maria B Moretto; José E Paz da Silva
Journal:  Biomed Pharmacother       Date:  2009-01-20       Impact factor: 6.529

8.  Ischemia modified albumin: A novel marker for acute coronary syndrome.

Authors:  R Chawla; Navendu Goyal; Rajneesh Calton; Shweta Goyal
Journal:  Indian J Clin Biochem       Date:  2006-03

9.  Impaired coronary flow reserve in patients with metabolic syndrome.

Authors:  Bahar Pirat; Huseyin Bozbas; Vahide Simsek; Aylin Yildirir; L Elif Sade; Yusuf Gursoy; Cihan Altin; Ilyas Atar; Haldun Muderrisoglu
Journal:  Atherosclerosis       Date:  2008-02-21       Impact factor: 5.162

10.  Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report.

Authors:  Agnieszka Piwowar; Maria Knapik-Kordecka; Maria Warwas
Journal:  Dis Markers       Date:  2008       Impact factor: 3.434

View more
  26 in total

Review 1.  Biological basis of depression in adults with diabetes.

Authors:  Shivam Champaneri; Gary S Wand; Saurabh S Malhotra; Sarah S Casagrande; Sherita Hill Golden
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

2.  Serum ischaemic-modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism.

Authors:  Varikasuvu Seshadri Reddy; P V L N Srinivasa Rao; M M Suchitra; Renu Garg
Journal:  Endocrine       Date:  2013-10-12       Impact factor: 3.633

3.  Author reply to: serum ischaemic-modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism.

Authors:  Inan Anaforoğlu; Kerem Ersoy; Ekrem Algün
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

4.  Evaluation of the Relationship Between Ischemia-Modified Albumin Levels and Thyroid Hormone Levels.

Authors:  Mufide Oncel; Aysel Kıyıcı; Serife Onen
Journal:  J Clin Lab Anal       Date:  2014-06-21       Impact factor: 2.352

5.  Postpartum weight retention is associated with elevated ratio of oxidized LDL lipids to HDL-cholesterol.

Authors:  Jatta Puhkala; Riitta Luoto; Markku Ahotupa; Jani Raitanen; Tommi Vasankari
Journal:  Lipids       Date:  2013-12       Impact factor: 1.880

6.  Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia.

Authors:  Renata da Silva Pereira; Etiane Tatsch; Guilherme Vargas Bochi; Helena Kober; Thiago Duarte; Greice Franciele Feyh dos Santos Montagner; José Edson Paz da Silva; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz; Rafael Noal Moresco
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

7.  Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels?

Authors:  Aysel Kiyici; Idris Mehmetoğlu; Hatice Karaoğlan; Hüseyin Atalay; Yalçin Solak; Süleyman Türk
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 8.  Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

Authors:  Kazuhiko Kotani; Satoshi Kimura; Alejandro Gugliucci
Journal:  J Physiol Biochem       Date:  2011-04-12       Impact factor: 4.158

9.  Ischemic heart diseases in Egypt: role of xanthine oxidase system and ischemia-modified albumin.

Authors:  Ola Sayed Ali; Hanan Muhammad Abdelgawad; Makram Sayed Mohammed; Rehab Refaat El-Awady
Journal:  Heart Vessels       Date:  2013-10-04       Impact factor: 2.037

10.  Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects.

Authors:  S R Mirhafez; M Ebrahimi; M Saberi Karimian; A Avan; M Tayefi; A Heidari-Bakavoli; M R Parizadeh; M Moohebati; M R Azarpazhooh; H Esmaily; M Nematy; M Safarian; G A Ferns; M Ghayour-Mobarhan
Journal:  Eur J Clin Nutr       Date:  2016-07-27       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.